Lipid-lowering treatment in hypercholesterolaemic patients: The CEPHEUS Pan-Asian survey

European Journal of Preventive Cardiology

Volumn 19, Issue 4, 2012, Pages 781-794

  Park, Jeong Euy ^a   Chiang, Chern En ^b   Munawar, Muhammad ^c   Pham, Gia Khai ^d   Sukonthasarn, Apichard ^e   Aquino, Anastacio R ^f   Khoo, Kah Lin ^g   Chan, Hon Wah Raymond ^h  

^a Sungkyunkwan University   (South Korea)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d Vietnam National Heart Association   (Viet Nam)

^e THAMMASAT UNIVERSITY   (Thailand)

^f St Louise University   (Philippines)

^g Pantai Medical Centre   (Malaysia)

^h QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Cardiovascular diseases; dyslipidemia; hypercholesterolaemia; low density lipoprotein; undertreatment

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 ACID ETHYL ESTER; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER;

ADULT; AGED; ASIA; CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HEALTH CARE SURVEY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TREATMENT DURATION; ARTICLE; ASIAN; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DOWN REGULATION; DRUG UTILIZATION; ETHNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870883505     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826710397100     Document Type: Review

References (32)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998 ; 339: 1349-1357
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA. 1999 ; 282: 2340-2346
3. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 ; 326: 1423-1423
4. Alter DA, Manuel DG, Gunraj N, Anderson G, Naylor CD, Laupacis A. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. Am J Med. 2004 ; 116: 540-545
5. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002 ; 106: 3143-3421
6. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005 ; 96: 53E - 59E
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239
8. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (Suppl 2). S1 - S113
9. Assmann G, Carmena R, Cullen P, Fruchart JC, Jossa F, Lewis B, et al. Coronary heart disease: reducing the risk: A worldwide view. International Task Force for the Prevention of Coronary Heart Disease. Circulation. 1999 ; 100: 1930-1938
10. Waters DD, Ku I. Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. J Am Coll Cardiol. 2009 ; 54: 1434-1437
11. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007 ; 11: 1-160
12. Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: A systematic review of randomized trials. Am J Cardiovasc Drugs. 2007 ; 7: 135-141
13. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: A meta-analysis involving 121,000 patients. Am J Med. 2008 ; 121: 24-33
14. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther. 2003 ; 41: 567-577
15. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997 ; 18: 1569-1582
16. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001 ; 22: 554-572
17. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2008 ; 197: 710-717
18. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: A comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 ; 373: 929-940
19. Hermans MP, Castro Cabezas M, Ferrières J, Feely J, Elisaf M, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010 ; 26: 445-454
20. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000 ; 160: 459-467
21. Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Ferrières J, et al. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J. 2009 ; 158: 860-866
22. Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: A multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009 ; 120: 28-34
23. Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008 ; 24: 1951-1963
24. Erhardt LR, Hobbs FD. A global survey of physicians' perceptions on cholesterol management: the From The Heart study. Int J Clin Pract. 2007 ; 61: 1078-1085
25. Hobbs FD, Erhardt LR, Rycroft C. The From The Heart study: A global survey of patient understanding of cholesterol management and cardiovascular risk, and physician-patient communication. Curr Med Res Opin. 2008 ; 24: 1267-1278
26. Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D. The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease. Am J Cardiovasc Drugs. 2006 ; 6: 383-391
27. Lee KK, Lee VW, Chan WK, Lee BS, Chong AC, Wong JC, et al. Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study. Value Health. 2008 ; 11 (Suppl 1). S91 - S98
28. Kisjanto J, Bonneux L, Prihartono J, Ranakusuma TA, Grobbee DE. Risk factors for stroke among urbanized Indonesian women of reproductive age: A hospital-based case-control Study. Cerebrovasc Dis. 2005 ; 19: 18-22
29. Batty GD, Shipley MJ, Gale CR, Mortensen LH, Deary IJ. Does IQ predict total and cardiovascular disease mortality as strongly as other risk factors? Comparison of effect estimates using the Vietnam Experience Study. Heart. 2008 ; 94: 1541-1544
30. Chung JST, Lee KKC, Tomlinson B, Lee VWY. Clinical and economic impact of clinical pharmacy service on hyperlipidemic management in Hong Kong. J Cardiovasc Pharmacol Ther. 2010 ;:
31. Ha DA, Chisholm D. Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy Plan. 2010 ;:
32. Tan F, Liew SF, Chan G, Toh V, Wong SY. Improving diabetes care in a public hospital medical clinic: report of a completed audit cycle. J Eval Clin Pract. 2010 ;: